The Study
Prevalence and breakdown of KRAS driver mutations in a large UK non-small cell lung cancer cohort
This study counted how often different KRAS mutations show up in lung cancer samples from UK patients. It’s like taking a big snapshot of what mutations are around — but it doesn’t tell us if the mutations make the cancer worse or better, just that they’re often found together.
Analysis score
Maximum 44 for a cross-sectional study.
Where the score came from
Scientists looked at lung cancer tissue samples from thousands of UK patients to see what types of KRAS gene changes they had, and if those changes were linked to immune markers like PD-L1.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 542 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — knowing which KRAS mutations are common helps doctors choose the right targeted drugs (like G12C inhibitors) for UK patients, but PD-L1 levels don't help predict KRAS status.
- 21,118 out of 3,283 lung cancer samples had KRAS mutations.
- 387% were Class I (especially G12C, G12V, G12D).
- 4PIK3CA and BRAF mutations often happened together.
- 5PD-L1 levels were similar in mutated and non-mutated tumors.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of Clinical Pathology
Year
2025
Authors
Isabella Niesner, K. Balbi, B. Poskitt, C. Gemma, Josep Linares, David Allen, Oliver Shutkever, Colin R Lindsay, P. Bennett, D. A. Moore
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.